Literature DB >> 15060621

SRC gene expression in human cancer: the role of transcriptional activation.

Scott M Dehm1, Keith Bonham.   

Abstract

Human pp60c-Src (or c-Src) is a 60 kDa nonreceptor tyrosine kinase encoded by the SRC gene and is the cellular homologue to the potent transforming v-Src viral oncogene. c-Src functions at the hub of a vast array of signal transduction cascades that influence cellular proliferation, differentiation, motility, and survival. c-Src activation has been documented in upwards of 50% of tumors derived from the colon, liver, lung, breast, and pancreas. Therefore, a major focus has been to understand the mechanisms of c-Src activation in human cancer. Early studies concentrated on post-translational mechanisms that lead to increased c-Src kinase activity, which often correlated with overexpression of c-Src protein. More recently, the discovery of an activating SRC mutation in a small subset of advanced colon tumors has been reported. In addition, elevated SRC transcription has been identified as yet another mechanism contributing significantly to c-Src activation in a subset of human colon cancer cell lines. Interestingly, histone deacetylase (HDAC) inhibitors, agents with well-documented anti-cancer activity, repress SRC transcription in a wide variety of human cancer cell lines. Analysis of the mechanisms behind HDAC inhibitor mediated repression could be utilized in the future to specifically inhibit SRC gene expression in human cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15060621     DOI: 10.1139/o03-077

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  58 in total

1.  The prognostic role of phospho-Src family kinase analysis in tongue cancer.

Authors:  Ofer Ben-Izhak; Victoria Cohen-Kaplan; Rafael M Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

2.  The importance of Src signaling in sarcoma.

Authors:  Quanchi Chen; Zifei Zhou; Liancheng Shan; Hui Zeng; Yingqi Hua; Zhengdong Cai
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

3.  Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry.

Authors:  Yi Chen; Mike Gruidl; Elizabeth Remily-Wood; Richard Z Liu; Steven Eschrich; Mark Lloyd; Aejaz Nasir; Marilyn M Bui; Emina Huang; David Shibata; Timothy Yeatman; John M Koomen
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

4.  Naringin suppresses the metabolism of A375 cells by inhibiting the phosphorylation of c-Src.

Authors:  Bingyu Guo; Yu Zhang; Qiang Hui; Hongyi Wang; Kai Tao
Journal:  Tumour Biol       Date:  2015-10-17

5.  Presenilin 1 affects focal adhesion site formation and cell force generation via c-Src transcriptional and posttranslational regulation.

Authors:  Dieter Waschbüsch; Simone Born; Verena Niediek; Norbert Kirchgessner; Irfan Y Tamboli; Jochen Walter; Rudolf Merkel; Bernd Hoffmann
Journal:  J Biol Chem       Date:  2009-01-27       Impact factor: 5.157

6.  Expression of N-myristoyltransferase in human brain tumors.

Authors:  Yanjie Lu; Ponniah Selvakumar; Kaiser Ali; Anuraag Shrivastav; Gagan Bajaj; Lothar Resch; Robert Griebel; Daryl Fourney; Kotoo Meguro; Rajendra K Sharma
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

Review 7.  The emerging role of lysine acetylation of non-nuclear proteins.

Authors:  Pierre Close; Catherine Creppe; Magali Gillard; Aurélie Ladang; Jean-Paul Chapelle; Laurent Nguyen; Alain Chariot
Journal:  Cell Mol Life Sci       Date:  2010-01-16       Impact factor: 9.261

8.  Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.

Authors:  Thorbjørn Krejsgaard; Claudia S Vetter-Kauczok; Anders Woetmann; Hermann Kneitz; Karsten W Eriksen; Paola Lovato; Qian Zhang; Mariusz A Wasik; Carsten Geisler; Elisabeth Ralfkiaer; Juergen C Becker; Niels Ødum
Journal:  Blood       Date:  2009-04-07       Impact factor: 22.113

Review 9.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

10.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.